Skip to content
Aubagio(teriflunomide)
Aubagio (teriflunomide) is a small molecule pharmaceutical. Teriflunomide was first approved as Aubagio on 2012-09-12. It is used to treat relapsing-remitting multiple sclerosis in the USA. It has been approved in Europe to treat multiple sclerosis and relapsing-remitting multiple sclerosis. The pharmaceutical is active against dihydroorotate dehydrogenase (quinone), mitochondrial.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
immune system diseasesD007154
Trade Name
FDA
EMA
Aubagio (generic drugs available since 2018-09-04)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Teriflunomide
Tradename
Company
Number
Date
Products
AUBAGIOSanofiN-202992 RX2012-09-12
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
aubagioNew Drug Application2020-11-19
teriflunomideANDA2023-04-20
teriflunomideANDA2023-04-20
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
relapsing-remitting multiple sclerosisEFO_0003929D020529—
Agency Specific
FDA
EMA
Expiration
Code
TERIFLUNOMIDE, AUBAGIO, SANOFI AVENTIS US
2024-10-30PED
2024-04-30M-61
TERIFLUNOMIDE, TERIFLUNOMIDE, ACCORD HLTHCARE
2023-09-08PC
TERIFLUNOMIDE, TERIFLUNOMIDE, AMNEAL PHARMS CO
2023-09-08PC
TERIFLUNOMIDE, TERIFLUNOMIDE, APOTEX
2023-09-08PC
TERIFLUNOMIDE, TERIFLUNOMIDE, GLENMARK PHARMS
2023-09-08PC
TERIFLUNOMIDE, TERIFLUNOMIDE, SANDOZ INC
2023-09-08PC
TERIFLUNOMIDE, TERIFLUNOMIDE, TEVA PHARMS USA
2023-09-08PC
TERIFLUNOMIDE, TERIFLUNOMIDE, WATSON LABS TEVA
2023-09-08PC
TERIFLUNOMIDE, TERIFLUNOMIDE, ZYDUS PHARMS
2023-09-08PC
Patent Expiration
Patent
Expires
Flag
FDA Information
Teriflunomide, Aubagio, Sanofi Aventis Us
91863462034-02-04U-1786
88027352030-09-14DP
67944102026-09-12U-1285
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AA: Selective immunosuppressants
— L04AA31: Teriflunomide
HCPCS
No data
Clinical
Clinical Trials
48 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple sclerosisD009103EFO_0003885G3517144228
Relapsing-remitting multiple sclerosisD020529EFO_0003929——91313
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Celiac diseaseD002446EFO_0001060K90.011———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1————1
Renal insufficiencyD051437HP_0000083N191————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Medication adherenceD055118EFO_0006344————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTERIFLUNOMIDE
INNteriflunomide
Description
Teriflunomide is an enamide obtained by formal condensation of the carboxy group of (2Z)-2-cyano-3-hydroxybut-2-enoic acid with the anilino group of 4-(trifluoromethyl)aniline. Used for the treatment of relapsing forms of multiple sclerosis and rheumatoid arthritis. It has a role as an EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor, a tyrosine kinase inhibitor, a hepatotoxic agent, a drug metabolite and a non-steroidal anti-inflammatory drug. It is a nitrile, an enol, an aromatic amide, an enamide, a member of (trifluoromethyl)benzenes and a secondary carboxamide.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C/C(O)=C(\C#N)C(=O)Nc1ccc(C(F)(F)F)cc1
Identifiers
PDB1D3H
CAS-ID163451-81-8
RxCUI1310520
ChEMBL IDCHEMBL973
ChEBI ID68540
PubChem CID54684141
DrugBankDB08880
UNII ID1C058IKG3B (ChemIDplus, GSRS)
Target
Agency Approved
DHODH
DHODH
Organism
Homo sapiens
Gene name
DHODH
Gene synonyms
NCBI Gene ID
1723
Protein name
dihydroorotate dehydrogenase (quinone), mitochondrial
Protein synonyms
Dihydroorotate oxidase, human complement of yeast URA1
Uniprot ID
Q6P176
Mouse ortholog
Dhodh (56749)
dihydroorotate dehydrogenase (quinone), mitochondrial (O35435)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Aubagio - Sanofi
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 3,140 documents
View more details
Safety
Black-box Warning
Black-box warning for: Aubagio, Teriflunomide, Teriflunomide
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
946 adverse events reported
View more details